The Safety and the Pharmacokinetics and Pharmacodynamics of a Pegylated Interferon Alpha-2a Formulation, Dong-A's DA-3021 |
Son, Han-Kil
(Department of Pharmacology, Yonsei University College of Medicine)
Lim, Ah-Young (Department of Pharmacology, Yonsei University College of Medicine) Lee, Dong-Hwan (Department of Pharmacology, Yonsei University College of Medicine) Jang, Seong-Bok (Department of Pharmacology, Yonsei University College of Medicine) Lee, Yoon-Jung (Department of Pharmacology, Yonsei University College of Medicine) Chung, Jae-Yong (Department of Pharmacology, Yonsei University College of Medicine) Park, Kyung-Soo (Department of Pharmacology, Yonsei University College of Medicine) |
1 | Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology. 2000;32(3):647-653. DOI ScienceOn |
2 | Fischer T, Aman J, van der Kuip H, Rudolf G, Peschel C, Aulitzky WE, Huber C. Inducti on of interferon regulatory factors 2'-5 oligoa denylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness. Br J Haematol, 1996;92(3):595-603. DOI ScienceOn |
3 | EMEA. European Medicines Agency Evaluati on of Medicines for Human Use. http://www. ema.europa.eu/docs/en_GB/document_library/S cientific_guideline/2009/09/WC500003517.pdf[O nline] (last visited on 23 Dec 2010) |
4 | Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L. Phase I trial of 40-kd branched pegylated interferon alfa - 2a for patients with advanced renal cell carcinoma. J Clin Oncol, 2001;19(5) :1312-1319. DOI |
5 | Schwarz KB, Mohan P, Narkewicz MR, Molleston JP, Nash SR, Hu S, Wang K, Gries JM. Safety, efficacy and pharmacokineti cs of peginterferon alpha2a (40 kd) in childre n with chronic hepatitis C . J Pediatr Gastro enterol Nutr, 2006;43(4):499-505. DOI ScienceOn |
6 | Zeuzem S, Welsch C, Herrmann E. Pharmaco kinetics of peginterferons. Semin Liver Dis, 2003;23 Suppl 1:23-28. DOI |
7 | Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchman n M. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int, 2007;20(7):583-590. DOI ScienceOn |
8 | Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulati on model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in hea thy subjects. Clin Pharmacol Ther, 1999;59(6): 636-646. |
9 | Bernd M. Pharmacokinetics of Peptides and P roteins. In: Pharmacokinetics and Pharmacody namics of Biotech Drugs. WILEY-VCH Verlag, 2006;22. |
10 | Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis, 2004;24 Suppl 2:33-38. DOI |
11 | Bernd M. Custom-Tailored Pharmacokinetics and Pharmacodynamics. In : Pharmacokinetics and Pharmacodynamics of Biotech Drugs WILEY-VCH Verlag, 2006;282. |
12 | Hochuli E. Interferon immunogenicity: technic al evaluation of interferon-alpha 2a. J Interfer on Cytokine Res, 1997;17 Suppl 1:S15-21. |
13 | Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetic s, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therap y Group. Clin Pharmacol Ther, 2000;68(5):556 -567. DOI ScienceOn |
14 | FDA. Clinical Pharmacology Review of Peg-i nterferon alfa-2a (Ro25-8310, PEGASYS). http: //www.fda.gov/downloads/Drugs/Development ApprovalProcess/HowDrugsareDevelopedandA pproved/ApprovalApplications/TherapeuticBiol ogicApplications/ucm094466.pdf [Online] (last visited on 23 Dec 2010). |